Skip to main content
Clinical Trials/NCT01991847
NCT01991847
Completed
Not Applicable

Feasibility Study of the PROTECT-trial (The Potential and Role Of Tertiary Prevention by Exercise in Colorectal Cancer Therapy)

Technical University of Munich1 site in 1 country50 target enrollmentJanuary 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Technical University of Munich
Enrollment
50
Locations
1
Primary Endpoint
Target sample size
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to determine the feasibility of a one year exercise training program in post-surgical patients with colorectal cancer.

Detailed Description

Apart from a genetic predisposition lifestyle factors (low physical activity, nutrition, and obesity) increase the risk of colorectal cancer. Furthermore, in observational studies increased physical activity has shown to improve the prognosis in patients after the diagnosis of colorectal cancer. However, there are currently no prospective randomized controlled trials which prove the causal relationship between exercise and prognosis in colorectal cancer patients. The long-term aim of this study is to evaluate whether physical activity of ≥ 18 MET-h (Metabolic equivalent task-hours) per week significantly improves disease free survival in colorectal cancer survivors (stage UICC II/III). In the first instance, structure-, process- as well as outcome-characteristics need to be investigated within a feasibility study (F-PROTECT). Essential aims are to establish collaborations with clinics and training centres, to achieve the required recruitment numbers, and to conduct the training intervention.

Registry
clinicaltrials.gov
Start Date
January 2014
End Date
April 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Technical University of Munich
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • histologically confirmed nonhereditary primary Stage II or III colon cancer diagnosis or rectal cancer
  • written informed consent in German
  • histopathologically confirmed R0-resection
  • start of guideline conformed adjuvant chemotherapy within 12 weeks after R0-resection in Stage III colon cancer diagnosis (if necessary in Stage III colon cancer diagnosis)

Exclusion Criteria

  • hereditary colon cancer diagnosis
  • R1 and R2 resection
  • clinically relevant complications during recovery
  • secondary neoplasm
  • non-continuance of guideline conformed therapy
  • uncontrolled infection
  • manifest cardiac disease (e.g. unstable CAD, heart failure (NYHA IV), malignant hypertension)
  • clinical relevant respiratory disease (GOLD IV)
  • musculoskeletal disorders severely restricting the patients mobility (e.g. gonarthrosis, coxarthrosis)
  • cirrhosis of the liver (Child B and C)

Outcomes

Primary Outcomes

Target sample size

Time Frame: one year

The primary outcome measure is to successfully recruit 50 colorectal cancer patients, and to achieve 70% compliance to regular exercise over one year.

Secondary Outcomes

  • Cancer related fatigue(at screening and 6 and 12 month after baseline)
  • Adverse and serious adverse events(one year)
  • Physical activity(at screening and 3, 6, 9, and 12 month after baseline)
  • Peak oxygen consumption(at baseline and 12 month after baseline)
  • Patient satisfaction(at 3, 6, 9, and 12 month after baseline)
  • Anxiety and depression(at screening and 6 and 12 month after baseline)
  • Cancer related quality of life(at screening and 6 and 12 month after baseline)
  • Quality of life in colorectal cancer(at screening and 6 and 12 month after baseline)

Study Sites (1)

Loading locations...

Similar Trials